{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T07:18:58Z","timestamp":1785827938651,"version":"3.56.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:00:00Z","timestamp":1669420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:00:00Z","timestamp":1669420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Key Research and Development Program of China","award":["2021YFC2701803"],"award-info":[{"award-number":["2021YFC2701803"]}]},{"name":"the China Antimicrobial Surveillance Network","award":["Independent Medical Grants from Pfizer, 2018QD100"],"award-info":[{"award-number":["Independent Medical Grants from Pfizer, 2018QD100"]}]},{"name":"Shanghai Antimicrobial Surveillance Network","award":["3030231003"],"award-info":[{"award-number":["3030231003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ceftobiprole is a fifth-generation cephalosporin which has been reported to have broad antibacterial spectrum when tested against bacteria collected from other countries except China. This study evaluated the in vitro activity of ceftobiprole in comparison with other comparators against clinically significant isolates collected across from China.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Susceptibility testing of ceftobiprole and comparators against 1163 clinically isolated Gram-positive and Gram-negative bacteria was performed with broth micro dilution method following the CLSI guidelines. All 110 <jats:italic>S. aureus<\/jats:italic> were susceptible to ceftobiprole with MIC<jats:sub>50\/90<\/jats:sub> of 1\/2\u00a0mg\/L for MRSA and 0.5\/1\u00a0mg\/L for MSSA. For Coagulase-negative <jats:italic>staphylococci<\/jats:italic> (CNS), MIC<jats:sub>50\/90<\/jats:sub> of ceftobiprole for MRCNS and MSCNS was 1\/2\u00a0mg\/L and 0.25\/0.5\u00a0mg\/L. Ceftobiprole demonstrated good potency against <jats:italic>E. faecalis<\/jats:italic> (MIC<jats:sub>50\/90<\/jats:sub> of 0.5\/1\u00a0mg\/L) but limited activity against <jats:italic>E. faecium<\/jats:italic> (MIC<jats:sub>50\/90<\/jats:sub> of\u2009&gt;\u200932\/\u2009&gt;\u200932\u00a0mg\/L). Ceftobiprole demonstrated potent activity against all 39 \u03b2-hemolytic <jats:italic>Streptococcus spp.<\/jats:italic> with MIC<jats:sub>50\/90<\/jats:sub>\u2009\u2264\u20090.015\/\u2009\u2264\u20090.015\u20132\u00a0mg\/L and 110 of PSSP with 98.2% susceptibility. Ceftobiprole inhibited all isolates of <jats:italic>H. influenzae<\/jats:italic> and <jats:italic>M. catarrhalis<\/jats:italic> at\u2009\u2264\u20091\u00a0mg\/L. 91.8% and 98.2% of the ESBL-negative <jats:italic>E. coli<\/jats:italic> and <jats:italic>K. pneumoniae<\/jats:italic> were susceptible to ceftobiprole, but most of the ESBL-positive or carbapenem-resistant strains were also resistant to ceftobiprole. Ceftobiprole inhibited 84.2% of carbapenem-susceptible <jats:italic>P. aeruginosa<\/jats:italic> and 94.1% of carbapenem-susceptible <jats:italic>A. baumannii<\/jats:italic> at\u2009\u2264\u20098\u00a0mg\/L, but only 52.6% of carbapenem-resistant <jats:italic>P. aeruginosa<\/jats:italic> and 5.3% of carbapenem-resistant <jats:italic>A. baumannii<\/jats:italic>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Ceftobiprole demonstrated good in vitro activity against a broad range of clinically relevant contemporary Gram-positive and Gram-negative bacterial isolates.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12866-022-02699-4","type":"journal-article","created":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T01:19:13Z","timestamp":1669511953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antimicrobial activity of ceftobiprole and comparator agents when tested against gram-positive and -negative organisms collected across China (2016\u20132018)"],"prefix":"10.1186","volume":"22","author":[{"given":"Yin","family":"Dandan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Yonggui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fupin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,26]]},"reference":[{"issue":"3","key":"2699_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327. https:\/\/doi.org\/10.1016\/S1473-3099(17)30753-3.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2699_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2008.12.012","volume":"34","author":"A Barbour","year":"2009","unstructured":"Barbour A, Schmidt S, Rand KH, Derendorf H. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents. 2009;34(1):1\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2008.12.012.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"2699_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.medmal.2016.10.004","volume":"47","author":"E Hodille","year":"2017","unstructured":"Hodille E, Delouere L, Bouveyron C, Meugnier H, Bes M, Tristan A, et al. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections. Med Mal Infect. 2017;47(2):152\u20137. https:\/\/doi.org\/10.1016\/j.medmal.2016.10.004.","journal-title":"Med Mal Infect"},{"issue":"13","key":"2699_CR4","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/14656566.2018.1516749","volume":"19","author":"V Falco","year":"2018","unstructured":"Falco V, Burgos J, Almirante B. Ceftobiprole medocaril for the treatment of community-acquired pneumonia. Expert Opin Pharmacother. 2018;19(13):1503\u20139. https:\/\/doi.org\/10.1080\/14656566.2018.1516749.","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"2699_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/14787210.2019.1667229","volume":"17","author":"DR Giacobbe","year":"2019","unstructured":"Giacobbe DR, De Rosa FG, Del Bono V, Grossi PA, Pea F, Petrosillo N, et al. Ceftobiprole: drug evaluation and place in therapy. Expert Rev Anti Infect Ther. 2019;17(9):689\u201398. https:\/\/doi.org\/10.1080\/14787210.2019.1667229.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl 3","key":"2699_CR6","first-page":"3","volume":"32 Suppl 3","author":"MI Morosini","year":"2019","unstructured":"Morosini MI, D\u00edez-Aguilar M, Cant\u00f3n R. Mechanisms of action and antimicrobial activity of ceftobiprole. Rev Esp Quimioter. 2019;32 Suppl 3(Suppl 3):3\u201310.","journal-title":"Rev Esp Quimioter."},{"issue":"6","key":"2699_CR7","doi-asserted-by":"publisher","first-page":"e02566","DOI":"10.1128\/AAC.02566-19","volume":"64","author":"RK Flamm","year":"2020","unstructured":"Flamm RK, Duncan LR, Hamed KA, Smart JI, Mendes RE, Pfaller MA. Ceftobiprole activity against bacteria from skin and skin structure infections in the United States from 2016 through 2018. Antimicrob Agents Chemother. 2020;64(6):e02566-e2619. https:\/\/doi.org\/10.1128\/AAC.02566-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"2699_CR8","first-page":"17","volume":"32 Suppl 3","author":"C Cill\u00f3niz","year":"2019","unstructured":"Cill\u00f3niz C, Domined\u00f2 C, Garcia-Vidal C, Torres A. Ceftobiprole for the treatment of pneumonia. Rev Esp Quimioter. 2019;32 Suppl 3(Suppl 3):17\u201323.","journal-title":"Rev Esp Quimioter."},{"issue":"1","key":"2699_CR9","doi-asserted-by":"publisher","first-page":"e01566","DOI":"10.1128\/AAC.01566-18","volume":"63","author":"MA Pfaller","year":"2019","unstructured":"Pfaller MA, Flamm RK, Mendes RE, Streit JM, Smart JI, Hamed KA, et al. Ceftobiprole activity against gram-positive and -negative pathogens collected from the United States in 2006 and 2016. Antimicrob Agents Chemother. 2019;63(1):e01566-e1618. https:\/\/doi.org\/10.1128\/AAC.01566-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2699_CR10","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1093\/jac\/dkaa306","volume":"75","author":"C Horner","year":"2020","unstructured":"Horner C, Mushtaq S, Livermore DM, BSAC Resistance Surveillance Standing Committee. Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance data. J Antimicrob Chemother. 2020;75(11):3239\u201343. https:\/\/doi.org\/10.1093\/jac\/dkaa306.","journal-title":"J Antimicrob Chemother."},{"issue":"6","key":"2699_CR11","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.ijantimicag.2018.01.006","volume":"51","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Huband MD, Streit JM, Flamm RK, Sader HS. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016). Int J Antimicrob Agents. 2018;51(6):848\u201353. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.01.006.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"2699_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ijantimicag.2013.11.005","volume":"43","author":"DJ Farrell","year":"2014","unstructured":"Farrell DJ, Flamm RK, Sader HS, Jones RN. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types. Int J Antimicrob Agents. 2014;43(4):323\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.11.005.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2699_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2017.12.020","volume":"91","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Flamm RK, Duncan LR, Streit JM, Castanheira M, Sader HS. Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015). Diagn Microbiol Infect Dis. 2018;91(1):77\u201384. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.12.020.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2699_CR14","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. CLSI supplement M100. Wayne: Clinical and Laboratory Standards Institute; 2019."}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-022-02699-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-022-02699-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-022-02699-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T01:21:31Z","timestamp":1669512091000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-022-02699-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,26]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2699"],"URL":"https:\/\/doi.org\/10.1186\/s12866-022-02699-4","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,26]]},"assertion":[{"value":"13 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We confirmed that all methods were carried out in accordance with relevant guidelines and regulations; all experimental protocols were approved by the Institutional Review Board of Huashan Hospital, Fudan University (No.2017\u2013321). None of human participants were directly involved in the study, so the informed consent was not applicable here.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"282"}}